Jeremy Schulenberg York

Title: Jeremy Schulenberg York: Innovator in Kinase Inhibitors

Introduction

Jeremy Schulenberg York is a notable inventor based in Indianapolis, IN (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of kinase inhibitors. His work is essential for advancing treatments for various diseases, including rheumatoid arthritis.

Latest Patents

Jeremy holds a patent for "Benzimidazoles and benzothiazoles as inhibitors of map kinase." This invention provides kinase inhibitors of Formula I, wherein W represents inter alia imidazol, oxazol, pyrazol, thiazol, or triazol, which are substituted by phenyl or thienyl. The disclosed compounds inhibit p-38 kinase and are useful in the treatment of metastasis or rheumatoid arthritis. He has 1 patent to his name.

Career Highlights

Jeremy is currently employed at Eli Lilly and Company, a leading pharmaceutical company known for its innovative research and development in the healthcare sector. His role at Eli Lilly allows him to contribute to groundbreaking research that has the potential to improve patient outcomes.

Collaborations

Throughout his career, Jeremy has collaborated with talented individuals such as Rosanne Bonjouklian and Jose Eugenio De Diego Gomez. These collaborations have fostered a productive environment for innovation and discovery.

Conclusion

Jeremy Schulenberg York is a distinguished inventor whose work in kinase inhibitors is paving the way for new treatments in medicine. His contributions to the field are invaluable and highlight the importance of innovation in healthcare.